STOCK TITAN

Kestra Medical director gets 7,217 RSUs, sells shares

KMTS director Mary Kay Ladone reported a new RSU award and a nondiscretionary share sale to cover tax withholding on vested equity.

(Neutral)
(Negative)
Form Type
4

Rhea-AI Filing Summary

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) reported that director Mary Kay Ladone had two equity-related transactions. On September 9, 2026, she received a grant of 7,217 restricted stock units, each convertible into one common share, scheduled to vest on September 9, 2027, subject to continued service. On September 8, 2026, she sold 3,908 common shares at a weighted average price of $25.1956 per share in a nondiscretionary “sell to cover” transaction to satisfy tax withholding obligations from the vesting and settlement of restricted stock units, with sale prices ranging from $24.91 to $25.43 per share. A prior pro rata distribution had included 17,512 common shares received from West Affum Holdings, L.P., referenced in her holdings.

Positive

  • None.

Negative

  • None.
Insider Ladone Mary Kay
Role Director
Sold 3,908 shs ($98K)
Type Security Shares Price Value
Grant/Award Common Shares F4 7,217 -- --
Sale Common Shares F1, F2, F3 3,908 $25.1956 $98K
Holdings After Transaction: Common Shares — 44,724 shares (Direct)
Footnotes (4)
  1. F1. The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.
  2. F2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $24.9100 to $25.4300. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
  3. F3. Includes 17,512 Common Shares received from West Affum Holdings, L.P., in a pro rata distribution exempt pursuant to Rule 16a-9.
  4. F4. The reported securities represent restricted stock units which each entitle the reporting person to receive one common share of the Issuer. The restricted stock units will vest on September 9, 2027, subject to the reporting person's continued service through such date.
Shares sold 3,908 shares Common shares sold on September 8, 2026 in a sell-to-cover transaction
Weighted average sale price $25.1956 per share Weighted average price for 3,908 KMTS shares sold on September 8, 2026
Sale price range $24.91 to $25.43 per share Range of prices at which the 3,908 shares were sold
RSUs granted 7,217 units Restricted stock units granted on September 9, 2026, each for one common share
RSU vesting date September 9, 2027 Vesting date for 7,217 restricted stock units subject to continued service
Pro rata distribution shares 17,512 shares Common shares received from West Affum Holdings, L.P. in a Rule 16a-9 exempt distribution
restricted stock units financial
"The reported securities represent restricted stock units which each entitle"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
sell to cover financial
"required to be sold by the reporting person pursuant to sell to cover"
Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.
weighted average price financial
"The price in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
pro rata distribution financial
"Common Shares received from West Affum Holdings, L.P., in a pro rata distribution"
A pro rata distribution is when a company or organization shares out money, assets, or benefits evenly among all eligible people based on their size or share. For example, if a company makes a profit and distributes it to shareholders, each person gets a portion proportional to how many shares they own. It ensures everyone gets their fair part based on their ownership or stake.
Rule 16a-9 regulatory
"in a pro rata distribution exempt pursuant to Rule 16a-9."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did KMTS director Mary Kay Ladone report on this Form 4?

She reported a grant of 7,217 restricted stock units on September 9, 2026, and a sale of 3,908 common shares on September 8, 2026, in connection with tax withholding on vested restricted stock units.

How many KMTS shares did Mary Kay Ladone sell and at what price?

She sold 3,908 common shares of KMTS at a weighted average price of $25.1956 per share. The filing states that sale prices ranged from $24.91 to $25.43 per share in this nondiscretionary sell-to-cover transaction.

Was the KMTS stock sale by Mary Kay Ladone part of a tax sell-to-cover transaction?

Yes. The filing states the 3,908-share sale was a nondiscretionary sale required to satisfy tax withholding obligations related to the vesting and settlement of restricted stock units, meaning it was structured as a sell-to-cover transaction.

What are the terms of Mary Kay Ladone’s new KMTS restricted stock units?

The filing reports 7,217 restricted stock units, each entitling her to receive one KMTS common share. These RSUs will vest on September 9, 2027, subject to her continued service with the company through that date.

Did Mary Kay Ladone’s KMTS transactions occur under a Rule 10b5-1 trading plan?

No. The Form 4 indicates no Rule 10b5-1 trading plan affirmation for these transactions. The sale is described instead as a nondiscretionary sell-to-cover to meet tax withholding obligations on vested restricted stock units.

What additional KMTS shares are referenced in Mary Kay Ladone’s holdings?

The filing notes that her holdings include 17,512 common shares received from West Affum Holdings, L.P. in a pro rata distribution that was exempt under Rule 16a-9, providing context for her overall ownership position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ladone Mary Kay

(Last)(First)(Middle)
C/O KESTRA MEDICAL TECHNOLOGIES, LTD.
3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)
KIRKLAND WASHINGTON 98033

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares09/08/2026S(1)3,908D$25.1956(2)37,507(3)D
Common Shares09/09/2026A7,217(4)A(4)44,724D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.
2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $24.9100 to $25.4300. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
3. Includes 17,512 Common Shares received from West Affum Holdings, L.P., in a pro rata distribution exempt pursuant to Rule 16a-9.
4. The reported securities represent restricted stock units which each entitle the reporting person to receive one common share of the Issuer. The restricted stock units will vest on September 9, 2027, subject to the reporting person's continued service through such date.
/s/ Traci S. Umberger as attorney-in-fact for Mary Kay Ladone09/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading